News from sosei heptares A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

05 Jun, 2020, 08:22 BST Sosei Heptares Notes Phase IIIb ARGON Study With Enerzair® Breezhaler® (QVM149) Meets Primary Endpoint in Patients With Uncontrolled Asthma

- Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily...


13 May, 2020, 08:51 BST Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2020

Sosei Group Corporation ("the Company"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first...


07 May, 2020, 09:00 BST Sosei Heptares Announces Further Scientific Progress with Orexin Agonist Program in Conjunction With Spin-off Companies Orexia and Inexia

Sosei Group Corporation ('the Company') (TSE: 4565) announces that it has made further significant progress with its orexin program, which is being...


01 May, 2020, 07:52 BST Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been Recommended for Approval in the European Union for Treating Uncontrolled Asthma

Sosei Group Corporation ("the Company"; TSE: 4565) notes that its strategic alliance partner Novartis (SWX: NOVN) announced that the European...


14 Apr, 2020, 09:00 BST Sosei Heptares to Apply its Structure-based Drug Design Expertise in New COVID-19 R&D Program

Sosei Group Corporation ("the Company") (TSE: 4565) today announces it will apply its unique structure-based drug design platform and capabilities to ...


25 Mar, 2020, 09:00 GMT Sosei Heptares Announces New Board Director Appointment and Executive Promotion

Sosei Group Corporation ("the Company"; TSE: 4565) today announces the appointment of Mr. Rolf Soderstrom as a new Board Director and the promotion...


20 Mar, 2020, 09:00 GMT Sosei Heptares Announces New Publication Highlighting the Potential of Structure-based Approaches to Generate Novel Peptide-based Drugs Targeting GPCRs

Sosei Group Corporation ("the Company") (TSE: 4565) announces that a review article entitled 'Advances in Therapeutic Peptides Targeting G...


13 Feb, 2020, 07:23 GMT Sosei Heptares Operational Highlights and Consolidated Results for the 12 Months Ended 31 December 2019

Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the twelve...


14 Jan, 2020, 00:05 GMT Sosei Heptares: Significant Progress by Orexia and Inexia With Orexin Agonist Program Triggers Next Tranche of Funding From Medicxi

Sosei Group Corporation ("the Company") (TSE: 4565) announces that significant scientific progress at its spin-off companies Orexia Limited...


24 Dec, 2019, 09:00 GMT Sosei Heptares Announces Nomination of a Third Clinical Candidate by Pfizer from Multi-target Drug Discovery Collaboration

Sosei Group Corporation ("the Company"; TSE: 4565) has been notified by its strategic alliance partner Pfizer that it has nominated a third clinical...


23 Dec, 2019, 08:00 GMT Sosei Heptares Announces the First Phase I Clinical Start From Its Multi-target Drug Discovery Collaboration With Pfizer

Sosei Group Corporation ("the Company") (TSE: 4565) has been notified by its strategic alliance partner Pfizer that it has dosed the first subject in ...


28 Nov, 2019, 09:11 GMT Sosei Heptares Announces That the COPD Treatment Ultibro® Breezhaler® has been Included in the National Reimbursement Drug List in China

Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro® Breezhaler® (an inhaled once-daily fixed-dose combination of...


19 Nov, 2019, 08:00 GMT Sosei Heptares Creates New World-Class International Scientific Advisory Board to Support Strategic Decision-Making Aligned with Corporate Objectives

Sosei Group Corporation ("the Company"; TSE: 4565) announces the formation of a new Scientific Advisory Board (SAB) to advise on the Company's...


12 Nov, 2019, 08:00 GMT Sosei Heptares Operational Highlights and Consolidated Results for the Nine Months Ended 30 September, 2019

Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the nine...


09 Oct, 2019, 08:00 BST Sosei Heptares to Receive US$3 Million Payment from Genentech on Nomination of a New GPCR Disease Target

Sosei Group Corporation ("the Company"; TSE: 4565) announces that it has been notified by its partner Genentech, a member of the Roche Group, of its...


01 Oct, 2019, 08:00 BST Sosei Heptares Notes the Announcement of Positive Results from Phase III IRIDIUM Study of Inhaled Combination QVM149 in Patients with Uncontrolled Asthma

Sosei Group Corporation ("the Company"; TSE: 4565) notes that Novartis has announced positive results from its Phase III IRIDIUM trial. The results...


12 Sep, 2019, 09:00 BST Sosei Heptares Investor R&D Event Highlights Innovative Research and Development Approaches and Strong Pipeline Momentum

Sosei Group Corporation ("the Company"; TSE: 4565) today held an Investor R&D Event in Tokyo, Japan, discussing how the integration of its...


13 Aug, 2019, 08:36 BST Sosei Heptares Operational Highlights and Consolidated Results for the First Half of FY2019

Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the first...


18 Jul, 2019, 07:37 BST Sosei Heptares to Receive US$2.5 Million Milestone Payment from Formosa Pharmaceuticals

Sosei Group Corporation ("the Company"; TSE: 4565) announces that Formosa Pharmaceuticals, Inc. ("Formosa") has received approval from the US Food...


10 Jun, 2019, 08:00 BST Sosei Heptares to Receive New $3 Million Milestone Payment from Pfizer, as It Advances a Second Candidate from the GPCR Collaboration for Clinical Development

Sosei Group Corporation ("the Company"); (TSE: 4565) and its strategic alliance partner Pfizer announce that a new clinical candidate from their...


24 May, 2019, 00:47 BST Sosei Heptares Notes That a Valid Marketing Authorization Application For QVM149, a Potential New Inhaled Combination Therapy For Asthma, Has Been Filed With the European Medicines Agency

Sosei Group Corporation ("the Company"; TSE: 4565) announces it has been notified today by its strategic alliance partner Novartis (SWX: NOVN) that...


22 May, 2019, 14:59 BST Sosei Heptares Notes New Positive Phase II Data for QVM149, a Potential Novel Inhaled Combination for Treating Asthma, Were Presented at ATS 2019

Sosei Group Corporation ("the Company"; TSE: 4565) notes that its partner Novartis presented key Phase II data for QVM149, a potential new inhaled...


14 May, 2019, 08:39 BST Sosei Heptares Reports Progress With Pfizer as Multi-target Collaboration Delivers First Candidate for Clinical Advancement

Sosei Group Corporation ("the Company"); (TSE: 4565) reports encouraging progress and initial success of its strategic multi-target drug discovery...


21 Mar, 2019, 23:51 GMT Sosei Heptares Announces that Ultibro® Breezhaler® and Seebri® Breezhaler® Launched in China for the Treatment of COPD

Sosei Group Corporation ("the Company"; TSE: 4565) confirms that Ultibro® Breezhaler® and Seebri® Breezhaler® have been launched by Novartis in China ...


20 Feb, 2019, 06:57 GMT Sosei Heptares Starts New Clinical Development Program

Sosei Group Corporation ("the Company"; TSE: 4565), announces that the first healthy subject has been dosed with a novel small molecule HTL0030310 in ...